These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 32704613)

  • 1. Synergistic Effect of Bypassing Agents and Sequence Identical Analogue of Emicizumab and Fibrin Clot Structure in the In Vitro Model of Hemophilia A.
    Zong Y; Antovic A; Soutari NMH; Antovic J; Pruner I
    TH Open; 2020 Apr; 4(2):e94-e103. PubMed ID: 32704613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents.
    Hartmann R; Feenstra T; Valentino L; Dockal M; Scheiflinger F
    J Thromb Haemost; 2018 Jun; ():. PubMed ID: 29888855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emicizumab improves the stability and structure of fibrin clot derived from factor VIII-deficient plasma, similar to the addition of factor VIII.
    Shimonishi N; Nogami K; Ogiwara K; Matsumoto T; Nakazawa F; Soeda T; Hirata M; Arai N; Shima M
    Haemophilia; 2020 May; 26(3):e97-e105. PubMed ID: 32157756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of emicizumab and bypassing agents in patients with hemophilia - An in vitro study.
    Schultz NH; Glosli H; Bjørnsen S; Holme PA
    Res Pract Thromb Haemost; 2021 Jul; 5(5):e12561. PubMed ID: 34263107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of bypassing agents in patients on emicizumab using global hemostasis assays.
    Kizilocak H; Marquez-Casas E; Phei Wee C; Malvar J; Carmona R; Young G
    Haemophilia; 2021 Jan; 27(1):164-172. PubMed ID: 33245833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicted coagulation potential using an in vitro simulated model of emicizumab prophylaxis and immune tolerance induction therapy in hemophilia A patients with inhibitor.
    Nakajima Y; Tonegawa H; Noguchi-Sasaki M; Nogami K
    Int J Hematol; 2021 Jun; 113(6):789-796. PubMed ID: 33635530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multimodal assessment of non-specific hemostatic agents for apixaban reversal.
    Martin AC; Gouin-Thibault I; Siguret V; Mordohay A; Samama CM; Gaussem P; Le Bonniec B; Godier A
    J Thromb Haemost; 2015 Mar; 13(3):426-36. PubMed ID: 25630710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa/factor X bispecific antibody emicizumab.
    Nogami K; Matsumoto T; Tabuchi Y; Soeda T; Arai N; Kitazawa T; Shima M
    J Thromb Haemost; 2018 Jun; 16(6):1078-1088. PubMed ID: 29645406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa.
    Bolliger D; Szlam F; Molinaro RJ; Escobar MA; Levy JH; Tanaka KA
    Haemophilia; 2010 May; 16(3):510-7. PubMed ID: 20050927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the safety of emicizumab in patients with hemophilia A.
    Langer AL; Etra A; Aledort L
    Expert Opin Drug Saf; 2018 Dec; 17(12):1233-1237. PubMed ID: 30462521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: In vitro and ex vivo analyses.
    Kjalke M; Kjelgaard-Hansen M; Andersen S; Hilden I
    J Thromb Haemost; 2021 Jul; 19(7):1687-1696. PubMed ID: 33819375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of FEIBA and emicizumab (SAFE): Dose escalation study evaluating the safety of in vivo administration of activated prothrombin complex concentrate in haemophilia A patients on emicizumab.
    Kizilocak H; Marquez-Casas E; Malvar J; Young G
    Haemophilia; 2023 Jan; 29(1):100-105. PubMed ID: 36287631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of the haemostatic effects of bypassing therapy using comprehensive coagulation assays in emicizumab prophylaxis-treated haemophilia A patients with inhibitors.
    Furukawa S; Nogami K; Shimonishi N; Nakajima Y; Matsumoto T; Shima M
    Br J Haematol; 2020 Sep; 190(5):727-735. PubMed ID: 32162680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stabilization of fibrin clots by activated prothrombin complex concentrate and tranexamic acid in FVIII inhibitor plasma.
    Dai L; Bevan D; Rangarajan S; Sørensen B; Mitchell M
    Haemophilia; 2011 Sep; 17(5):e944-8. PubMed ID: 21371192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. General haemostatic agents--fact or fiction?
    Hedner U
    Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():33-6. PubMed ID: 12214145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in venous clot structures between hemophilic mice treated with emicizumab
    Sefiane T; Maynadié H; Ettingshausen CE; Muczynski V; Heiligenstein X; Dumont J; Christophe OD; Denis CV; Casari C; Lenting PJ
    Haematologica; 2024 Jun; 109(6):1836-1848. PubMed ID: 38058210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Successful treatment by switching from activated prothrombin complex concentrate to emicizumab therapy in a hemophilia A patient with inhibitors].
    Sakamoto A; Nakadate H; Watanabe N; Ishiguro A
    Rinsho Ketsueki; 2020; 61(6):617-620. PubMed ID: 32624534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emicizumab Augments Thrombus Formation in Whole Blood from Patients with Hemophilia A under High Shear Flow Conditions.
    Yaoi H; Shida Y; Kitazawa T; Shima M; Nogami K
    Thromb Haemost; 2021 Mar; 121(3):279-286. PubMed ID: 32906155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concomitant Use of rFVIIa and Emicizumab in People with Hemophilia A with Inhibitors: Current Perspectives and Emerging Clinical Evidence.
    Linari S; Castaman G
    Ther Clin Risk Manag; 2020; 16():461-469. PubMed ID: 32547043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of systems biology to identify pharmacological mechanisms of thrombotic microangiopathy evoked by combined activated prothrombin complex concentrate and emicizumab.
    Valls R; Wagg J; Paz-Priel I; Man G; Artigas L; Jaccard G; Coma M; Schmitt C
    Sci Rep; 2023 Jun; 13(1):10078. PubMed ID: 37344529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.